Report Faults FDA Drug Safety Practices
Posted on: Tuesday, 10 October 2006, 12:00 CDT
The U.S. Food and Drug Administration is reportedly facing increasing criticism that it doesn't adequately protect people from unsafe medications.
Five experts who have advised the FDA on drug safety say the department's safety studies can miss serious problems with a pharmaceutical, both before and after its approval, The Washington Post reported Tuesday.
Specifically, the critics note the FDA does not have the authority to order drugs from the market, force changes in labeling, or issue sanctions against pharmaceutical companies that don't adequately monitor their products.
The five experts are current FDA Drug Safety Advisory Panel members Curt Furberg, a professor of medicine at Wake Forest University; Robyn Shapiro and Arthur Levin; and former panel members Peter Gross and Brian Strom.
The critique appears in the current issue of the journal Archives of Internal Medicine.
Source: United Press International
Related Articles
- IT&Amp;E, Inc. Expands Compliance, Validation and Clinical Support Staffing Services to Meet FDA's Aggressive Drug Safety Monitoring
- Revamping the U.S. Drug Safety System: Cleveland Clinic's Steven Nissen, MD, Among Featured Participants at Windhover's FDA/CMS Summit
- IOM: Wide Gaps in FDA Drug-Safety Process
- Senators plan bill to revamp FDA drug safety
- Analysis: FDA Drug-Safety Measure Nixed
- US advisers criticize FDA drug safety board
- Shire Plc - Statement Regarding the United States Food and Drug Administration Drug Safety and Risk Management Advisory Committee Meeting
- FDA Selects Ingenix for Drug Safety Monitoring and Support
- FDA Drug Safety Reviewer Pans Five Drugs
User Comments (0)
RSS Feeds